Seniors with cancer respond just as well as younger patients to immune checkpoint inhibitors -- drugs that take the brakes ...

1. Compared to receiving intravenous (directly into a vein (IV)) anti-cancer therapy in hospital outpatient clinics, we are uncertain whether receiving the same therapy at home affects the management ...

Key Takeaways Immunotherapy is as effective in seniors as in younger peopleSeniors’ immune systems are weaker, and thus less ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase ...

Persistent Epstein-Barr virus DNA or its resurgence during treatment was associated with worse survival in patients with ...

Enfortumab vedotin is now available for patients who received prior platinum-containing chemotherapy and a PD-1/L1 inhibitor ...

Bavencio improved survival in patients with bladder cancer, irrespective of diabetes status, according to an analysis of the ...

The week marked several FDA approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.

Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.